BYSANTI

This brand name is authorized in United States.

Active ingredients

The drug BYSANTI contains one active pharmaceutical ingredient (API):

1
UNII 7SV1ZOG031 - MILSAPERIDONE
 

The mechanism of action of milsaperidone in the treatment of schizophrenia in adults and the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults is unknown. However, the efficacy of milsaperidone in these conditions could be mediated through a combination of dopamine type 2 (D2) and serotonin type 2 (5-HT2) antagonism. Milsaperidone and iloperidone rapidly interconvert in vivo. Milsaperidone has an in vitro receptor binding profile similar to iloperidone.
 
Read more about Milsaperidone

Medication package inserts

Below package inserts are available for further reading:

Document Type Information Source  
 BYSANTI Tablet MPI, US: SPL/PLR FDA, National Drug Code (US)

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
US FDA, National Drug Code 43068-701, 43068-702, 43068-704, 43068-706, 43068-708, 43068-710, 43068-712, 43068-713, 43068-714, 43068-715

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈